Biomerica is a global biomedical technology company that develops patents manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits analyze blood urine nasal or fecal specimens to detect diseases food intolerances bacteria hormones antibodies antigens and other substances present in minute concentrations. The products aim to improve health and lower healthcare costs. They are sold worldwide mainly to clinical laboratories and point of care settings. Many of the tests carry CE marking and or have received clearance from the U S Food and Drug Administration.

Biomerica generates revenue from the sale of its diagnostic test kits. Key products include the EZ Detect colon disease home test the Aware Breast Self Exam product the inFoods IBS test and the hp detect test for Helicobacter pylori. Revenue comes from a network of distributors hospitals clinical laboratories medical research institutions medical schools pharmaceutical companies chain drugstores wholesalers physicians offices and e commerce channels. The company reports approximately seventy six customers comprised of thirty four foreign distributors four domestic distributors and the balance being domestic labs and other end users. Geographic sales are split roughly among Asia Europe North America Middle East and a small share from South America.

Biomerica operates in a competitive diagnostic market where many rivals are divisions of large pharmaceutical and medical device corporations with greater resources for research development manufacturing advertising and marketing. The company differentiates itself through proprietary product offerings high quality rapid test results and a strong patent portfolio. Its competitive advantage lies in the uniqueness of its tests such as the inFoods IBS and hp detect products which address specific niches in gastrointestinal health. Despite limited marketing scale Biomerica leverages its intellectual property to maintain a defensible position.

Biomerica serves clinical laboratories point of care facilities hospitals medical research institutions medical schools pharmaceutical companies chain drugstores wholesalers physicians offices and e commerce customers. The company does not disclose specific customer names but notes that its base includes a mix of domestic and foreign distributors as well as end users across the healthcare spectrum. Approximately seventy six customers account for its sales with a concentration of revenue among a few key distributors.